← Back to Search

Senolytic

Dasatinib + Quercetin for Obesity

Phase 2 & 3
Recruiting
Led By Nicolas Musi, MD
Research Sponsored by The University of Texas Health Science Center at San Antonio
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up week 4 and week 15

Summary

This trial will involve taking samples of fat tissue from the abdomen of all participants to study their cells and molecules. The participants will also undergo tests to measure their insulin sensitivity, glucose tolerance, and function of

Who is the study for?
This trial is for lean individuals aged 18-30 or those over 65 with a healthy BMI, from any race and living in the community. They must be sedentary, nondiabetic, not pregnant or breastfeeding, and willing to use effective contraception. Participants should have normal blood sugar levels and ECG readings.
What is being tested?
The study tests how lifestyle changes compare to senolytics (Dasatinib plus Quercetin) versus placebo in older obese adults. It involves baseline biopsies of belly fat for cellular analysis and checks on insulin sensitivity, glucose tolerance, and β-cell function.
What are the potential side effects?
Possible side effects include reactions at the biopsy site like pain or bruising; Dasatinib may cause immune system issues or bleeding problems; Quercetin could lead to headaches or tingling sensations.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~week 4 and week 15
This trial's timeline: 3 weeks for screening, Varies for treatment, and week 4 and week 15 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Glucose tolerance
Insulin sensitivity
Secondary study objectives
Senescence-associated secretory phenotype (SASP)

Trial Design

3Treatment groups
Experimental Treatment
Group I: Younger Lean GroupExperimental Treatment1 Intervention
Participants will be aged 18-30 years and have a BMI of 18.5 - 24.9 kg/m2
Group II: Older Obese GroupExperimental Treatment5 Interventions
Participants will be over 65 years of age with a BMI of 30-39.9 kg/m2.
Group III: Older Lean GroupExperimental Treatment1 Intervention
Participants will be over 65 years of age with a BMI of 18.5 to 24.9 kg/m2
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center at San AntonioLead Sponsor
476 Previous Clinical Trials
92,815 Total Patients Enrolled
6 Trials studying Obesity
990 Patients Enrolled for Obesity
Cedars-Sinai Medical CenterLead Sponsor
512 Previous Clinical Trials
163,204 Total Patients Enrolled
7 Trials studying Obesity
965 Patients Enrolled for Obesity
National Institute on Aging (NIA)NIH
1,789 Previous Clinical Trials
28,188,172 Total Patients Enrolled
47 Trials studying Obesity
13,473 Patients Enrolled for Obesity
~83 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top